STOCK TITAN

Amedisys Inc. - AMED STOCK NEWS

Welcome to our dedicated news page for Amedisys (Ticker: AMED), a resource for investors and traders seeking the latest updates and insights on Amedisys.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amedisys's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amedisys's position in the market.

Rhea-AI Summary
Amedisys, Inc. reports financial results for Q4 and full year 2023, showing increased net service revenue but a net loss due to merger costs. Adjusted EBITDA and net income per diluted share declined compared to 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
earnings
-
Rhea-AI Summary
Amedisys, Inc. partners with Patient Choice Laboratories to offer advanced molecular testing for infection diagnosis, aiming to improve patient care and outcomes. The collaboration utilizes the latest in diagnostic technology to swiftly and precisely identify pathogens in urine, respiratory, and wound infections, enhancing the accuracy and speed of infection testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.04%
Tags
none
-
Rhea-AI Summary
Amedisys, Inc. reports financial results for Q3 2023, with a decrease in net service revenue and net income compared to the previous year. Adjusted EBITDA and adjusted net income also decreased. The company will not conduct a quarterly earnings call due to a pending merger. Non-GAAP financial measures are provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
earnings
Rhea-AI Summary
Amedisys celebrates National Quality Week to highlight its commitment to quality care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
-
Rhea-AI Summary
Amedisys highlights the 988 Suicide and Crisis Lifeline for Suicide Prevention Awareness Month, aiming to raise awareness for suicide prevention and mental health. The three-digit number provides access to trained crisis counselors 24/7. Amedisys remains committed to providing compassionate care for patients' overall well-being.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
-
Rhea-AI Summary
Amedisys, Inc. (NASDAQ: AMED) reported financial results for the three and six-month periods ended June 30, 2023. Net service revenue decreased $4.9 million to $553.0 million compared to $557.9 million in 2022. Net loss attributable to Amedisys, Inc. was $80.3 million, inclusive of $125.5 million in merger costs, compared to net income of $29.6 million in 2022. Adjusted EBITDA was $74.6 million, adjusted net service revenue was $553.0 million, and adjusted net income was $44.9 million. For the six-month period, net service revenue increased to $1,109.4 million. Net loss attributable to Amedisys, Inc. was $55.0 million, inclusive of $126.2 million in merger costs, compared to net income of $61.3 million in 2022. Adjusted EBITDA was $132.5 million, adjusted net service revenue was $1,109.4 million, and adjusted net income was $77.6 million. Amedisys decided to suspend guidance on 2023 financial performance due to the pending merger with UnitedHealth Group Incorporated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
Rhea-AI Summary
Optum, a diversified health services company, has proposed an all-cash offer of $100 per share to combine with Amedisys, a leading provider of home health, hospice, and high-acuity care. The offer represents a 26% premium over Amedisys' most recent share price and aims to accelerate the provision of value-based care in the home, improving patient outcomes and experiences. The proposal has no financing contingency or condition and does not require shareholder approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.44%
Tags
none
-
Rhea-AI Summary
Optum, a diversified health services company, has proposed an all-cash offer of $100 per share to combine with Amedisys, a leading provider of home health, hospice, and high-acuity care. The offer represents a 26% premium over Amedisys' most recent share price and aims to accelerate the provision of value-based care in the home, improving patient outcomes and experiences. The proposal has no financing contingency or condition and does not require shareholder approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.44%
Tags
none
Amedisys Inc.

Nasdaq:AMED

AMED Rankings

AMED Stock Data

3.02B
31.94M
2.26%
96.17%
9.6%
Home Health Care Services
Health Care and Social Assistance
Link
US
Baton Rouge

About AMED

amedisys is a leading provider of healthcare in the home with a vision of becoming the premiere solution for patients across the country to age in place. from home health to hospice to personal care, amedisys team members provide quality, clinically-distinctive care to more than 376,000 patients every year. every life is precious and tells an incredible story, and we celebrate that each day by honoring our patients with genuine, personal attention. everything we do, from the boardroom to our nationwide network of care centers, is centered on the best care possible for those who have entrusted us with their well-being and comfort. we work closely with doctors and other healthcare providers to coordinate services, and every patient has an individual plan of care that meets their specific needs. amedisys recognizes that nothing we do is possible without our incredible team. for all employees, whether they’re on the front lines delivering direct care or supporting our clinical team, this i